FDA Approves New Treatment for Parkinson's Disease

2006 ◽  
Brain ◽  
2021 ◽  
Author(s):  
Qing Wang ◽  
Yuqi Luo ◽  
K Ray Chaudhuri ◽  
Richard Reynolds ◽  
Eng-King Tan ◽  
...  

Abstract Parkinson's disease is a common neurodegenerative disease in which gastrointestinal symptoms may appear prior to motor symptoms. The gut microbiota of patients with Parkinson's disease shows unique changes, which may be used as early biomarkers of disease. Alteration in gut microbiota composition may be related to the cause or effect of motor or non-motor symptoms, but the specific pathogenic mechanisms are unclear. The gut microbiota and its metabolites have been suggested to be involved in the pathogenesis of Parkinson's disease by regulating neuroinflammation, barrier function and neurotransmitter activity. There is bidirectional communication between the enteric nervous system and the central nervous system, and the microbiota-gut-brain axis may provide a pathway for the transmission of α-synuclein. We highlight recent discoveries and alterations of the gut microbiota in Parkinson's disease, and highlight current mechanistic insights on the microbiota-gut-brain axis in disease pathophysiology. We discuss the interactions between production and transmission of α-synuclein and gut inflammation and neuroinflammation. In addition, we also draw attention to diet modification, use of probiotics and prebiotics and fecal microbiota transplantation as potential therapeutic approaches that may lead to a new treatment paradigm for Parkinson's disease.


1990 ◽  
Vol 53 (11) ◽  
pp. 1015-1015 ◽  
Author(s):  
R Kapoor ◽  
N Turjanski ◽  
J Frankel ◽  
B Kleedorfer ◽  
A Lees ◽  
...  

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Meir Plotnik ◽  
Nir Giladi ◽  
Jeffrey M. Hausdorff

Several gait impairments have been associated with freezing of gait (FOG) in patients with Parkinson's disease (PD). These include deteriorations in rhythm control, gait symmetry, bilateral coordination of gait, dynamic postural control and step scaling. We suggest that these seemingly independent gait features may have mutual interactions which, during certain circumstances, jointly drive the predisposed locomotion system into a FOG episode. This new theoretical framework is illustrated by the evaluation of the potential relationships between the so-called “sequence effect”, that is, impairments in step scaling, and gait asymmetry just prior to FOG. We further discuss what factors influence gait control to maintain functional gait. “Triggers”, for example, such as attention shifts or trajectory transitions, may precede FOG. We propose distinct categories of interventions and describe examples of existing work that support this idea: (a) interventions which aim to maintain a good level of locomotion control especially with respect to aspects related to FOG; (b) those that aim at avoiding FOG “triggers”; and (c) those that merely aim to escape from FOG once it occurs. The proposed theoretical framework sets the stage for testable hypotheses regarding the mechanisms that lead to FOG and may also lead to new treatment ideas.


2021 ◽  
Author(s):  
Syeda Najam Zehra ◽  
Ishrat Younus ◽  
Saima Mahmood Malhi ◽  
Muhammad Liaquat Raza ◽  
Azfar Athar Ishaqui ◽  
...  

Abstract One of the major causes of neurological disorders is degeneration of neurons which is commonly termed as Neurodegeneration. It is well documented that two of the neurodegenerative disorders i.e., Alzheimer’s Disease & Parkinson Disease comes in top fifteen causes of deaths in United States of America. Due to the neuroprotective property of adenosine A2a receptor antagonists (ZM241385) was evaluated in haloperidol mouse model of Parkinson’s disease. Our results reveal significant antidopaminergic effects of adenosine A2A receptor antagonist that support its utilization as a new treatment approach in Parkinson’s diseases.


2021 ◽  
Vol 1025 ◽  
pp. 230-235
Author(s):  
Subashini Raman ◽  
Syed Mahmood ◽  
Ayah R. Hilles ◽  
Azizur Rahman

Parkinson’s Disease ongoing progression treatment demonstrated that new treatment had indicated a promising potential to suppress better the motor and non-motor symptoms arising in PD. There are various pre-existing treatment strategies besides therapeutic drugs used in treating PD. This review discusses newly approved therapeutic medications, current advancements and new strategies to overcome Parkinson’s. It includes deep Brain Stimulation, Focused Ultrasound Surgery and Glial cell line-derived neurotrophic factor (GDNP) treatment in suppressing Parkinson’s Disease symptoms.


Sign in / Sign up

Export Citation Format

Share Document